Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.58 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424631 | 1.00 | METAP2 (0.58) | METAP2METAP1LMNAMMP2BMP1 | |
| SCHEMBL3620878 | 1.00 | METAP2 (0.58) | METAP2METAP1LMNAMMP2BMP1 | |
| Hydrochloric Acid SCHEMBL4798841 | 0.98 | METAP2 (0.56) | METAP2METAP1LMNAMMP2BMP1 | |
| Hydrochloric Acid SCHEMBL1424630 | 0.98 | METAP2 (0.56) | METAP2METAP1LMNAMMP2BMP1 | |
| Hydrochloric Acid SCHEMBL919140 | 0.98 | METAP2 (0.56) | METAP2METAP1LMNAMMP2BMP1 | |
| SCHEMBL25380893 | 0.91 | METAP2 (0.48) | METAP2METAP1ALDH1A1 | |
| SCHEMBL7513774 | 0.85 | METAP2 (0.49) | METAP2METAP1MMP2EPHX1ALDH1A1 | |
| SCHEMBL8330172 | 0.83 | METAP2 (0.53) | METAP2METAP1MMP2BMP1ALDH1A1 | |
| SCHEMBL9555738 | 0.83 | METAP2 (0.47) | METAP2ALDH1A1NPSR1SLC1A3SLC1A2 | |
| SCHEMBL21118051 | 0.83 | METAP2 (0.47) | METAP2ALDH1A1NPSR1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176901-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176901-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008085608-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176901-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | METAP2 124/4885METAP1 142/4885LMNA 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.